3 NEWS : FDA approves GSK's RSV vaccine for high-risk adults ages 50 to 59, expanding shot's reach - CNBC #NewYork #news
- FDA approves GSK's RSV vaccine for high-risk adults ages 50 to 59, expanding shot's reach CNBC
- GSK Vaccine to Prevent Respiratory-Tract Disease Approved for Expanded Use MarketWatch
- GSK RSV Vaccine Wins US Approval for Younger Age Group Bloomberg
- FDA approves first RSV vaccine for at-risk adults in their 50s CBS News
- GSK exec lauds 'great start' to RSV vaccine uptake as Arexvy nabs label expansion in adults 50-59 FiercePharma
Publicar un comentario